Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jeffords Rx Re-Importation Bill Gains Sen. Gorton's Support

Executive Summary

Sen. Jeffords' (R-Vt.) prescription drug re-importation bill has gained the support of another border-state Republican: Sen. Gorton of Washington.

You may also be interested in...



Drug pricing

Senate Health Committee hearing on "Prescription Drug Costs" will take place July 18 at 9:30 a.m. Committee Chairman Jeffords (R-Vt.) has introduced legislation that would attempt to address drug pricing by permitting pharmacies and wholesalers to import prescription drugs. Jeffords held a hearing on June 13 that focused on importation issues pertinent to drug safety and pricing (1"The Pink Sheet" June 19, p. 9)

Drug pricing

Senate Health Committee hearing on "Prescription Drug Costs" will take place July 18 at 9:30 a.m. Committee Chairman Jeffords (R-Vt.) has introduced legislation that would attempt to address drug pricing by permitting pharmacies and wholesalers to import prescription drugs. Jeffords held a hearing on June 13 that focused on importation issues pertinent to drug safety and pricing (1"The Pink Sheet" June 19, p. 9)

CRADA "Reasonable Price" Clause Becomes Part Of HHS Approps Bill

"Reasonable" pricing for drugs developed with federal funding is closer to making a comeback with passage of an amendment to the fiscal 2001 Labor/HHS/ Education appropriations bill in the House.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel